| Literature DB >> 26740807 |
Ilona Mihaylova Gyuleva1, Kalina Ivanova Penkova2, Ivanka Tankova Rupova1, Delyana Yonkova Panova1, Jana Nikolaeva Djounova1.
Abstract
A 10-year survey of immune status of nuclear power plant (NPP) workers was assessed by cellular and humoral immune parameters. The cumulative doses of NPP workers were in the range of 0.06 to 766.36 mSv. The results did not show significant deviations in the studied parameters of cellular and humoral immunity, but a tendency of elevated values in CD3+4+ helper inducers cells, especially its CD4+62L+ subpopulation, regulatory CD4+25+ cells, CD8+28+ cytotoxic subpopulation, and immunoglobulin M, was established. The observed trend of the above-mentioned parameters could be interpreted by assumption that while the adaptation processes are dominated with low prevalence of T-helper (Th) 1 immune response to cumulative doses less than 100 mSv, a switch to Th-2 response occurred at doses above 100 mSv. The impact of a number of other confounding factors on the immune system does not allow definitive conclusions about the direct radiation-induced changes in immune parameters.Entities:
Keywords: immunoglobulin; immunology; ionizing radiation; low-dose effects; lymphocytes
Year: 2015 PMID: 26740807 PMCID: PMC4679204 DOI: 10.1177/1559325815611901
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
NPP Personnel: Groups According to Received Doses, Average Age and Length of Employment.
| Personnel | Average Age, Yearsa | Lenght of Service, Yearsa | Received Dose, mSva | ||
|---|---|---|---|---|---|
| Group | Dose, mSv | n | |||
| Control | 0 | 65 (49 males and 16 females) | 46 ± 8 | 19 ± 8 | 0 |
| 1 | 0.1-20 | 103 (93 males and 10 females) | 43 ± 7 | 16 ± 8 | 9.53 ± 5.8 |
| 2 | 20.1-100 | 117 (112 males and 5 females) | 42 ± 8 | 16 ± 8 | 49.42 ± 21.7 |
| 3 | 100.1-200 | 66 (64 males and 2 females) | 45 ± 7 | 18 ± 6 | 141.95 ± 30.4 |
| 4 | >200 | 153 (males) | 45 ± 6 | 20 ± 6 | 354.48 ± 120.3 |
Abbreviation: NPP, nuclear power plant.
a Indicate the standard deviation (±SD).
Health Status of NPP Workers.
| Condition | Health Status | Groupsa | ||||
|---|---|---|---|---|---|---|
| Control, % | 0.1-20 mSv, % | 20-100 mSv, % | 100-200 mSv, % | >200, mSv, % | ||
| Mobius hypertonicus | Healthy | 81.8 | 66.7 | 64.5 | 68.4 | 62.1 |
| With disease | 18.2 | 33.3 | 35.5 | 31.6 | 37.9 | |
| Cardio vascular diseases | Healthy | 78.8 | 66.7 | 64.5 | 63.2 | 62.1 |
| With disease | 21.2 | 33.3 | 35.5 | 36.8 | 37.9 | |
| Obesities | Healthy | 84.8 | 85.2 | 74.2 | 57.9 | 93.1 |
| With disease | 15.2 | 14.8 | 25.8 | 42.1 | 6.9 | |
| Diabetes mellitus | Healthy | 97.0 | 926 | 96.8 | 100.0 | 96.6 |
| With disease | 3.0 | 7.4 | 3.2 | - | 3.4 | |
| Hepatitis (inactive, not chronic) | Healthy | 97.0 | 88.9 | 90.3 | 89.5 | 93.1 |
| With disease | 3.0 | 11.1 | 9.7 | 10.5 | 6.9 | |
| Vaccinations and virus diseases in last month | No | 84.8 | 85.2 | 93.5 | 89.5 | 89.7 |
| Yes | 15.2 | 14.8 | 6.5 | 10.5 | 10.3 | |
| Gastrointestinal diseases | Healthy | 89.2 | 93.6 | 93.4 | 94.9 | 94.1 |
| With disease | 10.8 | 6.4 | 6.6 | 5.1 | 5.9 | |
| Pulmonary diseases | Healthy | 100.0 | 96.8 | 97.8 | 96.6 | 97.4 |
| With disease | - | 3.2 | 2.2 | 3.4 | 2.6 | |
a Data are presented as percent of all individuals in each group.
Reference Valuesa for Lymphocyte Subsets and Immunoglobulin.
| Lymphocyte Subsets as Percentage of Lymphocyte Count | ||
|---|---|---|
| Indices | Percentage Values | Absolute Values, cell/µL |
| CD4+CD62L− | 6%-20% | 120-460 |
| CD4+CD62L+ | 22%-60% | 620-1050 |
| CD4+CD25+ | 5%-14% | 20-240 |
| CD8+CD28+ | 3%-11% | 210-438 |
| CD8+CD38+ | 13%-26% | 230-550 |
| Immunoglobulins | ||
| Indices | Values, g/L | |
| IgG | 8-18 | |
| IgA | 0.9-4.50 | |
| IgM | 0.7-2.80 | |
| IgG | 8-18 | |
a Reference values for the Bulgarian population provided by the Central Laboratory of Clinical Immunology, University Hospital “Alexandrovska” (Sofia, Bulgaria); 5th percentile to 95th percentile range.
Figure 1.Relative values of CD3+4+, CD4+62L−, CD4+62L+ T lymphocytes.
Variation Analysis of CD4+CD62L−, CD4+CD62L+, Activated CD4+25+, Cytotoxic CD8+28+, and Activated CD8+38+ T Lymphocyte in NPP Workers.
| Parameters | Groups | Persons, N | X ± SD, % | X ± SD, cells/µL | X ± SD,subp%/popul% |
|---|---|---|---|---|---|
| CD4+CD62L− T lymphocytes | Control | 62 | 11.89 ± 4.2 | 269.74 ± 139.3 | |
| First group: doses 0.1-20 mSv | 92 | 12.56 ± 6.1 | 290.03 ± 142.7 | ||
|
|
| ||||
| Second group: doses 20.1-100 mSv | 76 | 12.05 ± 5.1 | 266.93 ± 131.3 | ||
|
|
| ||||
| Third group: doses 100.1-200 mSv | 56 | 11.04 ± 5.1 | 265.96 ± 126.4 | ||
|
|
| ||||
| Fourth group: doses above 200 mSv | 123 | 12.09 ± 4.4 | 292.30 ± 135.5 | ||
|
|
| ||||
| CD4+CD62L+ T lymphocytes | Control | 62 | 32.24 ± 6.4 | 712.03 ± 249.6 | |
| First group: doses 0.1-20 mSv | 92 | 27.77 ± 8,3 | 645.86 ± 249.5 | ||
|
|
| ||||
| Second group: doses 20.1-100 mSv | 76 | 28.76 ± 6.7 | 648.88 ± 256.7 | ||
|
|
| ||||
| Third group: doses 100.1-200 mSv | 56 | 29.16 ± 9.6 | 735.89 ± 315.4 | ||
|
|
| ||||
| Fourth group: doses above 200 mSv | 123 | 31.24 ± 8.5 | 732.56 ± 269.9 | ||
|
|
| ||||
| CD4+25+%/ CD4% | |||||
| CD4+25+ T lymphocytes | Control | 64 | 12.47 ± 6.64 | 276.9 ± 162.2 | 27.88 ± 13.7 |
| First group: doses 0.1-20 mSv | 94 | 9.38 ± 5.55 | 217.4 ± 140.8 | 23.21 ± 11.8 | |
|
|
|
| |||
| Second group: doses 20.1-100 mSv | 81 | 10.83 ± 6.44 | 234.9 ± 170.0 | 27.44 ± 17.5 | |
|
|
|
| |||
| Third group: doses 100.1-200 mSv | 59 | 11.78 ± 5.73 | 293.9 ± 176.1 | 30.49 ± 13.9 | |
|
|
|
| |||
| Fourth group: doses above 200 mSv | 123 | 12.06 ± 6.02 | 294.7 ± 175.0 | 28.76 ± 14.6 | |
|
|
|
| |||
| CD8+28+%/ CD8% | |||||
| Cytotoxic T lymphocytes (CD8+28+) | Control | 61 | 14.85 ± 3.5 | 343.44 ± 143.0 | 58.80 ± 12.6 |
| First group: doses 0.1-20 mSv | 94 | 15.88 ± 4.9 | 366.22 ± 135.7 | 55.67 ± 18.1 | |
|
|
|
| |||
| Second group: doses 20.1-100 mSv | 74 | 15.20 ± 4.8 | 343.62 ± 157.9 | 56.12 ± 16.4 | |
|
|
|
| |||
| Third group: doses 100.1-200 mSv | 55 | 14.07 ± 4.0 | 351.42 ± 132.4 | 57.61 ± 20.5 | |
|
|
|
| |||
| Fourth group: doses above 200 mSv | 123 | 13.48 ± 3.7 | 325.47 ± 136.1 | 51.40 ± 17.3 | |
|
|
|
| |||
| Activated CD3+8+ T Lymphocytes (CD8+38+) | Control | 44 | 14.86 ± 5.8 | 324.05 ± 160.2 | |
| First group: doses 0.1-20 mSv | 58 | 16.91 ± 5.7 | 388.53 ± 157.4 | ||
|
|
| ||||
| Second group: doses 20.1-100 mSv | 46 | 16.85 ± 7.3 | 368.11 ± 174.4 | ||
|
|
| ||||
| Third group: doses 100.1-200 mSv | 41 | 15.61 ± 8.8 | 368.07 ± 187.4 | ||
|
|
| ||||
| Fourth group: doses above 200 mSv | 84 | 13.79 ± 5.6 | 339.59 ± 177.3 | ||
|
|
|
Note: Boldface P values show significance of results.
Frequency Analysis of Studied Immune Parameters in NPP Workers given as a Percentage of the Number of Participants Who had Cell Counts Under, Within, or Above Reference Range.
| Parameters | Groups | Under Reference Range | Reference Range | Above Reference Range |
|---|---|---|---|---|
| CD4+62L− | Control | 6.3% | 88.9% | 4.8% |
| First group | 4.3% | 83.7% | 12% | |
| Second group | 9.2% | 82.9% | 7.9% | |
| Third group | 1.8% | 92.9% | 5.4% | |
| Fourth group | 4.9% | 84.6% | 10.6% | |
| CD4+62L+ | Control | 42.9% | 46% | 11.1% |
| First group | 50% | 46.7% | 3.3% | |
| Second group | 52.6% | 39.5% | 7.9% | |
| Third group | 41.1% | 42.9% | 16.1% | |
| Fourth group | 38.2% | 52% | 9.8% | |
| CD4+25+ | Control | 7.7% | 58% | 33.8% |
| First group | 18.1% | 63.8% | 18.1% | |
| Second group | 13.6% | 61.7% | 24.7% | |
| Third group | 8.5% | 62.7% | 28.8% | |
| Fourth group | 9.8% | 62.6% | 27.6% | |
| CD8+28+ | Control | 22.6% | 74.2% | 3.2% |
| First group | 26.6% | 60.6% | 12.8% | |
| Second group | 33.8% | 55.4% | 10.8% | |
| Third group | 30.9% | 65.5% | 3.6% | |
| Fourth group | 44.7% | 51.2% | 4.1% | |
| IgG | Control | 13.8% | 73.8% | 12.3% |
| First group | 7.8% | 87.4% | 4.9% | |
| Second group | 10.3% | 80.2% | 9.5% | |
| Third group | 4.6% | 78.5% | 16.9% | |
| Fourth group | 9.2% | 82.4% | 8.5% | |
| IgA | Control | 4.6% | 86.2% | 9.2% |
| First group | 7.8% | 82.5% | 9.7% | |
| Second group | 1.7% | 91.3% | 7.0% | |
| Third group | 1.5% | 90.8% | 7.7% | |
| Fourth group | 2.6% | 91.5% | 5.9% | |
| IgM | Control | 4.6% | 87.7% | 7.7% |
| First group | 0% | 86.4% | 13.6% | |
| Second group | 0.9% | 89.7% | 9.5% | |
| Third group | 1.5% | 87.7% | 9.8% | |
| Fourth group | 4.6% | 83.7% | 11.8% |
Abbreviations: Ig, immunoglobulin; NPP, nuclear power plant.
Immune Parameters of Smokers and Alcohol Consumers.
| Parameters | Under Ref. Range | Reference Range | Above Ref. Range | |||
|---|---|---|---|---|---|---|
| Nonsmokers | Smokers | Nonsmokers | Smokers | Nonsmokers | Smokers | |
| Smokers | ||||||
| CD4+62L− % / | 7.7% | 4.0% | 86.5% | 83.7% | 5.8% | 12.4% |
| CD4+62L+ % / | 54.2% | 39.6% | 40.0% | 50.0% | 5.8% | 10.4% |
| CD4+25+ % / | 16.7% | 9.8% | 65.4% | 60.8% | 17.9% | 29.4% |
| CD4+25+ abs/ | 0 | 0 | 65.4% | 50.0% | 34.6% | 50.0% |
| Alcohol Consumers | Nonalcohol Consumers | Alcohol Consumers | Nonalcohol Consumers | Alcohol Consumers | Nonalcohol Consumers | Alcohol Consumers |
| CD8+28+ abs/ | 17.3% | 10.6% | 68.3% | 64.1% | 14.4% | 25.3% |
| Ig M / | 0.0% | 3.2% | 90.3% | 79.5% | 9.7% | 17.3% |
Abbreviation: Ig, immunoglobulin.
Figure 2.CD4+25+ T lymphocytes.
Figure 3.Cytotoxic T lymphocytes (CD8+28+).
Figure 4.Activated T lymphocytes (CD8+38+).
Immunoglobulin G, A, and M.
| Groups | Immunoglobulin G, g/L | Immunoglobulin A, g/L | Immunoglobulin M, , g/L | |
|---|---|---|---|---|
| Control: 65 persons | X ± SD | 12.37 ± 4.07 | 2.26 ± 1.13 | 1.49 ± 0.60 |
| N | 65 | 65 | 65 | |
| First group: 103 persons doses 0.1-20 mSv | X ± SD | 11.53 ± 3.66 | 2.64 ± 1.45 | 1.75 ± 0.71 |
| N | 103 | 103 | 103 | |
|
|
|
| ||
| Second group: 116 persons doses 20.1-100 mSv | X ± SD | 12.31 ± 4.32 | 2.42 ± 1.15 | 1.52 ± 0.72 |
| N | 116 | 116 | 116 | |
|
|
|
| ||
| Third group: 65 persons doses 100.1-200 mSv | X ± SD | 13.35 ± 4.91 | 2.67 ± 1.02 | 1.60 ± 0.66 |
| N | 65 | 65 | 65 | |
|
|
|
| ||
| Fourth group: 153 persons doses above 200 mSv | X ± SD | 12.26 ± 3.86 | 2.49 ± 1.08 | 1.47 ± 0.71 |
| N | 153 | 153 | 153 | |
|
|
|
| ||
Figure 5.Immunoglobulin G, A, and M.